These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38458152)

  • 21. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells.
    Le Moignic A; Malard V; Benvegnu T; Lemiègre L; Berchel M; Jaffrès PA; Baillou C; Delost M; Macedo R; Rochefort J; Lescaille G; Pichon C; Lemoine FM; Midoux P; Mateo V
    J Control Release; 2018 May; 278():110-121. PubMed ID: 29630987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
    Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
    Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy.
    Fan Y; Kuai R; Xu Y; Ochyl LJ; Irvine DJ; Moon JJ
    Nano Lett; 2017 Dec; 17(12):7387-7393. PubMed ID: 29144754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.
    den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Toonen LW; Figdor CG; Ruers TJ; Adema GJ
    Cancer Res; 2006 Jul; 66(14):7285-92. PubMed ID: 16849578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity.
    Yang X; Lian K; Meng T; Liu X; Miao J; Tan Y; Yuan H; Hu F
    ACS Appl Mater Interfaces; 2018 Oct; 10(39):33532-33544. PubMed ID: 30192498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell-Penetrating Peptide Enhanced Antigen Presentation for Cancer Immunotherapy.
    Wu H; Zhuang Q; Xu J; Xu L; Zhao Y; Wang C; Yang Z; Shen F; Liu Z; Peng R
    Bioconjug Chem; 2019 Aug; 30(8):2115-2126. PubMed ID: 31339694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
    Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
    ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.
    Ali OA; Verbeke C; Johnson C; Sands RW; Lewin SA; White D; Doherty E; Dranoff G; Mooney DJ
    Cancer Res; 2014 Mar; 74(6):1670-81. PubMed ID: 24480625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy.
    van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG
    Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
    Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
    J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines.
    Wen CC; Chen HM; Chen SS; Huang LT; Chang WT; Wei WC; Chou LC; Arulselvan P; Wu JB; Kuo SC; Yang NS
    J Biomed Sci; 2011 Jun; 18(1):44. PubMed ID: 21689407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unprecedented Chiral Nanovaccines for Significantly Enhanced Cancer Immunotherapy.
    Liu H; Xie Z; Zheng M
    ACS Appl Mater Interfaces; 2022 Sep; 14(35):39858-39865. PubMed ID: 36007113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
    Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
    ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A versatile supramolecular nanoadjuvant that activates NF-κB for cancer immunotherapy.
    Xu Y; Wang Y; Yang Q; Liu Z; Xiao Z; Le Z; Yang Z; Yang C
    Theranostics; 2019; 9(11):3388-3397. PubMed ID: 31244959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational design of Polymeric Hybrid Micelles to Overcome Lymphatic and Intracellular Delivery Barriers in Cancer Immunotherapy.
    Li H; Li Y; Wang X; Hou Y; Hong X; Gong T; Zhang Z; Sun X
    Theranostics; 2017; 7(18):4383-4398. PubMed ID: 29158834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.